PDTC enables type I TRAIL signaling in type II follicular lymphoma cells.
Based on Bcl-X(L) overexpression studies we identified type I and type II follicular lymphoma cell lines in response to TRAIL. We demonstrate here that either amount of caspase-8 activation or Bid cleavage could not define the dependence on mitochondria. Furthermore, an inhibitor of NF-kappaB, PDTC, enabled TRAIL to activate type I apoptotic pathway in type II cells. However, an inhibitor of IKK did not switch apoptosis to type I pathway in type II cells, indicating that NF-kappaB might not be responsible for the switch.
Nuutinen
Ulla
U
Department of Clinical Microbiology, Institute of Clinical Medicine, University of Kuopio, Kuopio, Finland. ulla-maija.nuutinen@uku.fi
Simelius
Niina
N
Ropponen
Antti
A
Eeva
Jonna
J
Mättö
Mikko
M
Eray
Mine
M
Pellinen
Riikka
R
Wahlfors
Jarmo
J
Pelkonen
Jukka
J
D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis; D001483:Base Sequence; D053181:Caspase 8 / Q000378:metabolism; D045744:Cell Line, Tumor; D017931:DNA Primers; D004789:Enzyme Activation; D005434:Flow Cytometry; D006801:Humans; D008224:Lymphoma, Follicular / Q000378:metabolism* / Q000473:pathology; D016297:Mutagenesis, Site-Directed; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D011392:Proline / Q000031:analogs & derivatives* / Q000494:pharmacology; D015398:Signal Transduction; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism*; D013859:Thiocarbamates / Q000494:pharmacology*; D051020:bcl-X Protein / Q000378:metabolism
D000970:Antineoplastic Agents; D017931:DNA Primers; D016328:NF-kappa B; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human; D013859:Thiocarbamates; D051020:bcl-X Protein; C066229:prolinedithiocarbamate; D011392:Proline; D053181:Caspase 8